Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone

Naim M Maalouf, John R. Poindexter, Beverley A Huet, Orson W Moe, Khashayar Sakhaee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Idiopathic uric acid nephrolithiasis is characterized by an overly acidic urine pH caused by the combination of increased acid production and inadequate buffering of urinary protons by ammonia. A large proportion of uric acid stone formers exhibit features of the metabolic syndrome. We previously demonstrated that thiazolidinediones improved the urinary biochemical profile in an animal model of the metabolic syndrome. In this proof-of-concept study, we examined whether the thiazolidinedione pioglitazone can also ameliorate the overly acidic urine in uric acid stone formers. Thirty-six adults with idiopathic uric acid nephrolithiasis were randomized to pioglitazone 30 mg/day or matching placebo for 24 weeks. At baseline and study end, participants underwent collection of blood and 24-hour urine in an inpatient research unit while consuming a fixed metabolic diet, followed by assessment of the ammoniagenic response to an acute oral acid load. Twenty-eight participants completed the study. Pioglitazone treatment improved features of the metabolic syndrome. Pioglitazone also reduced net acid excretion and increased urine pH (5.37 to 5.59), the proportion of net acid excreted as ammonium, and ammonium excretion in response to an acute acid load, whereas these parameters were unchanged with placebo. Treatment of patients with idiopathic uric acid nephrolithiasis with pioglitazone for 24 weeks led to a reduction in the acid load presented to the kidney and a more robust ammoniagenesis and ammonium excretion, resulting in significantly higher urine pH. Future studies should consider the impact of this targeted therapy on uric acid stone formation.

Original languageEnglish (US)
Pages (from-to)1262-1268
Number of pages7
JournalKidney international
Volume95
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

pioglitazone
Uric Acid
Nephrolithiasis
Acids
Urine
Ammonium Compounds
Placebos
Thiazolidinediones
Ammonia
Protons
Inpatients
Therapeutics
Animal Models
Diet

Keywords

  • insulin resistance
  • metabolic syndrome
  • nephrolithiasis
  • pioglitazone
  • thiazolidinedione
  • uric acid

ASJC Scopus subject areas

  • Nephrology

Cite this

Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone. / Maalouf, Naim M; Poindexter, John R.; Huet, Beverley A; Moe, Orson W; Sakhaee, Khashayar.

In: Kidney international, Vol. 95, No. 5, 01.05.2019, p. 1262-1268.

Research output: Contribution to journalArticle

@article{a624e44bbc5044a2bef17fbd173a1a99,
title = "Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone",
abstract = "Idiopathic uric acid nephrolithiasis is characterized by an overly acidic urine pH caused by the combination of increased acid production and inadequate buffering of urinary protons by ammonia. A large proportion of uric acid stone formers exhibit features of the metabolic syndrome. We previously demonstrated that thiazolidinediones improved the urinary biochemical profile in an animal model of the metabolic syndrome. In this proof-of-concept study, we examined whether the thiazolidinedione pioglitazone can also ameliorate the overly acidic urine in uric acid stone formers. Thirty-six adults with idiopathic uric acid nephrolithiasis were randomized to pioglitazone 30 mg/day or matching placebo for 24 weeks. At baseline and study end, participants underwent collection of blood and 24-hour urine in an inpatient research unit while consuming a fixed metabolic diet, followed by assessment of the ammoniagenic response to an acute oral acid load. Twenty-eight participants completed the study. Pioglitazone treatment improved features of the metabolic syndrome. Pioglitazone also reduced net acid excretion and increased urine pH (5.37 to 5.59), the proportion of net acid excreted as ammonium, and ammonium excretion in response to an acute acid load, whereas these parameters were unchanged with placebo. Treatment of patients with idiopathic uric acid nephrolithiasis with pioglitazone for 24 weeks led to a reduction in the acid load presented to the kidney and a more robust ammoniagenesis and ammonium excretion, resulting in significantly higher urine pH. Future studies should consider the impact of this targeted therapy on uric acid stone formation.",
keywords = "insulin resistance, metabolic syndrome, nephrolithiasis, pioglitazone, thiazolidinedione, uric acid",
author = "Maalouf, {Naim M} and Poindexter, {John R.} and Huet, {Beverley A} and Moe, {Orson W} and Khashayar Sakhaee",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.kint.2018.11.024",
language = "English (US)",
volume = "95",
pages = "1262--1268",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone

AU - Maalouf, Naim M

AU - Poindexter, John R.

AU - Huet, Beverley A

AU - Moe, Orson W

AU - Sakhaee, Khashayar

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Idiopathic uric acid nephrolithiasis is characterized by an overly acidic urine pH caused by the combination of increased acid production and inadequate buffering of urinary protons by ammonia. A large proportion of uric acid stone formers exhibit features of the metabolic syndrome. We previously demonstrated that thiazolidinediones improved the urinary biochemical profile in an animal model of the metabolic syndrome. In this proof-of-concept study, we examined whether the thiazolidinedione pioglitazone can also ameliorate the overly acidic urine in uric acid stone formers. Thirty-six adults with idiopathic uric acid nephrolithiasis were randomized to pioglitazone 30 mg/day or matching placebo for 24 weeks. At baseline and study end, participants underwent collection of blood and 24-hour urine in an inpatient research unit while consuming a fixed metabolic diet, followed by assessment of the ammoniagenic response to an acute oral acid load. Twenty-eight participants completed the study. Pioglitazone treatment improved features of the metabolic syndrome. Pioglitazone also reduced net acid excretion and increased urine pH (5.37 to 5.59), the proportion of net acid excreted as ammonium, and ammonium excretion in response to an acute acid load, whereas these parameters were unchanged with placebo. Treatment of patients with idiopathic uric acid nephrolithiasis with pioglitazone for 24 weeks led to a reduction in the acid load presented to the kidney and a more robust ammoniagenesis and ammonium excretion, resulting in significantly higher urine pH. Future studies should consider the impact of this targeted therapy on uric acid stone formation.

AB - Idiopathic uric acid nephrolithiasis is characterized by an overly acidic urine pH caused by the combination of increased acid production and inadequate buffering of urinary protons by ammonia. A large proportion of uric acid stone formers exhibit features of the metabolic syndrome. We previously demonstrated that thiazolidinediones improved the urinary biochemical profile in an animal model of the metabolic syndrome. In this proof-of-concept study, we examined whether the thiazolidinedione pioglitazone can also ameliorate the overly acidic urine in uric acid stone formers. Thirty-six adults with idiopathic uric acid nephrolithiasis were randomized to pioglitazone 30 mg/day or matching placebo for 24 weeks. At baseline and study end, participants underwent collection of blood and 24-hour urine in an inpatient research unit while consuming a fixed metabolic diet, followed by assessment of the ammoniagenic response to an acute oral acid load. Twenty-eight participants completed the study. Pioglitazone treatment improved features of the metabolic syndrome. Pioglitazone also reduced net acid excretion and increased urine pH (5.37 to 5.59), the proportion of net acid excreted as ammonium, and ammonium excretion in response to an acute acid load, whereas these parameters were unchanged with placebo. Treatment of patients with idiopathic uric acid nephrolithiasis with pioglitazone for 24 weeks led to a reduction in the acid load presented to the kidney and a more robust ammoniagenesis and ammonium excretion, resulting in significantly higher urine pH. Future studies should consider the impact of this targeted therapy on uric acid stone formation.

KW - insulin resistance

KW - metabolic syndrome

KW - nephrolithiasis

KW - pioglitazone

KW - thiazolidinedione

KW - uric acid

UR - http://www.scopus.com/inward/record.url?scp=85064070479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064070479&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2018.11.024

DO - 10.1016/j.kint.2018.11.024

M3 - Article

C2 - 30795852

AN - SCOPUS:85064070479

VL - 95

SP - 1262

EP - 1268

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -